|
MTP joint synovial hypertrophy (US)
|
R2
|
58.1% (18)
|
45.2% (14)
|
p = 1.000
|
| |
R5
|
74.2% (23)
|
51.6% (16)
|
p = 0.344
|
| |
L2
|
61.3% (19)
|
35.5% (11)
|
p = 0.267
|
| |
L5
|
67.7% (21)
|
54.8% (17)
|
p = 0.754
|
|
MTP joint synovitis (Doppler US)
|
R2
|
6.5% (2)
|
6.5% (2)
|
p = 1.000
|
| |
R5
|
9.7% (3)
|
3.2% (1)
|
p = 0.625
|
| |
L2
|
3.2% (1)
|
0% (0)
|
p = 1.000
|
| |
L5
|
9.7% (3)
|
6.5% (2)
|
p = 1.000
|
|
MTP joint erosion (US)
|
R2
|
25.8% (8)
|
25.8% (8)
|
p = 0.250
|
| |
R5
|
74.2% (23)
|
51.6% (16)
|
p = 0.727
|
| |
L2
|
9.7% (3)
|
12.9% (4)
|
p = 1.000
|
| |
L5
|
61.3% (19)
|
58.1% (18)
|
p = 1.000
|
|
Plantar forefoot bursal hypertrophy (US)
|
R
|
83.9% (26)
|
67.7% (21)
|
p = 1.000
|
| |
L
|
80.6% (25)
|
69.2% (18)
|
p = 0.508
|
|
Clinically detectable plantar forefoot bursae
|
R
|
41.9% (13)
|
32.3% (10)
|
p = 0.012
|
| |
L
|
35.5% (11)
|
19.4% (6)
|
p = 0.453
|
|
Clinically detectable MTP joint synovitis
|
R
|
45.2% (14)
|
25.8% (8)
|
p = 0.375
|
| |
L
|
25.8% (8)
|
16.1% (5)
|
p = 0.070
|
